Tech Company Financing Transactions

Asceneuron Funding Round

Novo Holdings, EQT Life Sciences and Johnson & Johnson Innovation invested in a $100 million Series C capital raise for Asceneuron. This venture round was announced on 7/16/2024.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Life Sciences

Mailing Address

EPFL Innovation Park Bâtiment B
Lausanne, CH-1015
Switzerland

Phone

Undisclosed

Website

www.asceneuron.com

Email Address

Not Recorded

Overview

We have one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients. Asceneuron has two small molecule O-GlcNAcase inhibitors (ASN51 and ASN90) that leverage a central protein modification system to slow protein aggregation. Both ASN51 and ASN90 have completed 3 Phase 1 studies, demonstrating high O-GlcNAcase inhibition in the brain.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Barbara Pavik

        

Chief Operating Officer

Sandra Millet

        

VP - Bus. Development

Andrin Cerletti

        

VP - R & D

Ryan Schubert

        

VP - Regulatory Affairs

Ruhi Ahmed

        

Browse more venture capital transactions:

Prev: 7/16/2024: Omni Fiber venture capital transaction
Next: 7/16/2024: Cardurion Pharma venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary